论文部分内容阅读
目的探讨替格瑞洛联合阿司匹林治疗急性冠脉综合征(ACS)的临床疗效。方法选取160例ACS患者作为研究对象,根据随机数字表法均分为两组,各80例。对照组给予阿司匹林治疗,观察组在对照组治疗基础上加以替格瑞洛治疗。治疗3个月,对比两组临床疗效、治疗前后血小板聚集率和凝血指标变化及心血管事件。结果观察组治疗总有效率为96.25%,高于对照组的85.00%(P<0.05);治疗后两组血小板聚集率较治疗前降低,凝血指标较治疗前改善(P<0.05),且观察组优于对照组(P<0.05)。观察组心血管事件发生率为3.75%低于对照组的25.00%(P<0.05)。结论阿司匹林与替格瑞洛联合治疗ACS可提高临床疗效,减少血小板聚集率,改善血液凝血状况,心血管事件发生率。
Objective To investigate the clinical efficacy of ticagrelor combined with aspirin in the treatment of acute coronary syndrome (ACS). Methods A total of 160 patients with ACS were enrolled in this study. All patients were divided into two groups according to the random number table (n = 80). The control group was given aspirin, and the observation group was treated with ticagrelor on the basis of the control group. Treatment for 3 months, compared two groups of clinical efficacy, platelet aggregation rate before and after treatment and coagulation changes and cardiovascular events. Results The total effective rate of the observation group was 96.25%, which was higher than that of the control group (85.00%, P <0.05). The platelet aggregation rate of the two groups was lower than that before treatment, and the coagulation index was improved (P <0.05) Group than the control group (P <0.05). The incidence of cardiovascular events in the observation group was 3.75% lower than that in the control group (25.00%, P <0.05). Conclusion The combination of aspirin and ticagrelor can improve the clinical curative effect, reduce the rate of platelet aggregation, improve the blood coagulation status and the incidence of cardiovascular events.